Affimed is a private biopharmaceutical company specializing in the development of recombinant antibodies. The company's research engine, based around three distinct antibody libraries and proprietary antibody formats, is driving the development of a strong, broad portfolio of antibodies that target cancer and other diseases. The unique properties of these libraries allow Affimed to identify antibodies against even the most difficult of targets.
To be the leader in antibody research, Affimed has assembled one of the industry's most powerful research engines as a formidable resource for in-house antibody discovery. The core of this technology comprises three distinct antibody libraries that can be screened using phage display to identify antibodies to address even the most difficult of targets.
Contact Information
Address:
Phone: Fax: Web: Contact:
Technologiepark Im Neuenheimer Feld 582 Heidelberg 69120 Germany +49 (0)6221 65307 0 +49 (0)6221 65307 77 http://www.affimed.com Dr. Rolf H. Günther +49 (0)6221 65307 0
Company Facts
Founded:
May 2000
Founders:
Prof. Dr. Melvyn Little
CEO:
Dr. Rolf H. Günther
CTO or technical lead:
Prof. Dr. Melvyn Little
CFO or finance director:
Dr. Florian Fischer
Head of Sales:
n/a
Head of Marketing:
Northbank Communications
Stage:
Public
Category:
Biotechnology & Healthcare
Sector:
Biopharmaceuticals
Employees:
23
Profitability:
Pre-revenue
Funding raised:
Yes
Funding sought:
Yes
Seeking Partnerships:
Yes
Non-executive Board Members
Gerhard Ries
Frank Mühlenbeck
Michael Sheffery
Mark Wegter
Key Customers
Not Available
Key Business Partners
Not Available
Key Competitors
Not Available
Capital Raised
Date
Size
Investors
To view this information you must be signed in and subscribed to the online dataservice, sign in here.
To read more about the Online data service click here
Public Offerings
Date
Type
Exchange
No public offerings
Data
27,633 Tech investments From our Online Data Service
